Astex Pharmaceuticals making progress at Barcelona symposium
Astex Pharmaceuticals is set to make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics in Barcelona, Spain.
The Astex presentations at the Barcelona symposium, which ends today (25 October) focus on its novel small-molecule CBP/p300 HAT domain inhibitor, ASTX528, in preclinical development, and its Phase II-ready MDM2 antagonist, ASTX295.
Astex, which is based on Cambridge Science Park, is a wholly owned subsidiary of Otsuka Pharmaceutical Co, based in Tokyo, Japan. Founded in 1999, Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system.
ASTX528 aims to overcome the dose-limiting tolerability issues which have held back previous CBP/p300 HAT domain inhibitors. Astex is interested in discussing the further development of ASTX528 with potential partners.
ASTX295 was discovered by Astex in collaboration with the Cancer Research UK Drug Discovery Unit at Newcastle University. The compound was designed to overcome the on-target toxicity seen in the first generation MDM2 antagonist compounds.
Latest news
Most read
- 1
Why delays are expected on the Cambridgeshire guided busway
3 - 2
The Crown Estate unveils Cambridge Business Park redevelopment plans, with new offices, labs, homes, leisure and retail space
- 3
ViaNautis Bio partners Eli Lilly to leverage polyNaut platform
- 4
Expansion of Cambridge Biomedical Campus to south on cards
1 - 5
Prison for 37-year-old who stole from Cambridge stores